---
title: "Sinopharm Sets 2025 AGM to Approve Dividend, Guarantees and Share Issuance Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287829686.md"
description: "Sinopharm Group Co. has scheduled its 2025 AGM for June 18, 2026, in Shanghai. Shareholders will review financial statements, proposed dividends, and seek approval for directors' remuneration and auditor appointments. The meeting will also authorize the board to issue new shares and provide guarantees for subsidiaries, enhancing financial flexibility. The latest analyst rating for Sinopharm stock (HK:1099) is a Buy with a target price of HK$22.50."
datetime: "2026-05-27T22:58:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287829686.md)
  - [en](https://longbridge.com/en/news/287829686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287829686.md)
---

# Sinopharm Sets 2025 AGM to Approve Dividend, Guarantees and Share Issuance Mandate

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Sinopharm Group Co ( (HK:1099) ) has shared an update.

Sinopharm Group has called its 2025 annual general meeting for 18 June 2026 in Shanghai, where shareholders will review the board and supervisory committee reports, audited financial statements, and the proposed profit distribution and final dividend for 2025. The meeting will also seek approval for directors’ and supervisors’ remuneration, confirm the appointment and pay of domestic and international auditors, and authorise the board to provide guarantees for subsidiaries up to 30% of total assets.

In addition, shareholders will be asked to grant the board a general mandate to issue new Domestic Shares and H shares, including through instruments such as convertible bonds and warrants, and to sell or transfer treasury shares within a defined mandate period. These approvals, if passed, would give management broader financial and capital-raising flexibility while maintaining compliance with Hong Kong listing rules, and will shape Sinopharm’s balance-sheet management and growth capacity over the coming year.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

**More about Sinopharm Group Co**

Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical distributor and healthcare services provider, operating through a network that spans drug distribution, retail pharmacies, and related medical supply chains. Listed in Hong Kong, the group focuses on supplying medicines and healthcare products across the mainland China market and to overseas customers through its H share listing.

**Average Trading Volume:** 5,714,234

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$54.77B

For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)

## Related News & Research

- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)](https://longbridge.com/en/news/284328826.md)
- [Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow](https://longbridge.com/en/news/279810360.md)
- [Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base](https://longbridge.com/en/news/284128644.md)
- [Sinopharm Group Co (SHTDF) Gets a Buy from CLSA](https://longbridge.com/en/news/284466436.md)